|
Follow the links below to find information about medications that are used to treat people with dementia.
Created January 2009
Printer friendly page
| Results 1 to 20 displayed. |
|
1
2
|
| Title: |
Thioridazine for dementia
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
Behavioural problems are common in dementia and are a significant source of caregiver burden. Thioridazine has significant sedative effect, and it is thought that this is the main mechanism of action in calming and controlling the patient. However, phar...
|
| Date: |
Apr 2009
|
| Title: |
Hydergine for dementia
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
Hydergine has been used to treat patients with either dementia, or 'age-related' cognitive symptoms. Hydergine may offer benefit to some patients, possibly at doses of 4.5 to 9.0 mg per day, with possibly greater benefit to younger subjects and inpatien...
|
| Date: |
Mar 2009
|
| Title: |
Treating dementia
|
| Publisher: |
Australian Prescriber
|
| Description: |
Describes the diagnosis of dementia, and types, assessment and planning, drug and non-drug therapies for the condition.
|
| Date: |
Feb 2009
|
| Title: |
Yizhi capsule for vascular dementia
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
Vascular dementia (VD) is a syndrome or diagnosis that has different causes and clinical manifestations relating to several different vascular mechanisms and changes in the brain. It influences a patient's quality of life seriously. 'Yizhi capsule' is b...
|
| Date: |
Jan 2009
|
| Title: |
Cannabinoids for the treatment of dementia
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
Cannabinoids are compounds derived from the cannabis plant (Cannabis sativa). Laboratory studies have indicated that cannabinoids may regulate some of the processes that lead to neurodegeneration. This suggests that cannabinoids could be useful in the t...
|
| Date: |
Nov 2008
|
| Title: |
Valproate preparations for agitation in dementia
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
An updated review (October 2008) of valproate treatment of agitation in demented patients failed to show any improvement in agitation among treated patients compared with those not receiving treatment, and also demonstrated a higher rate of harmful effe...
|
| Date: |
Oct 2008
|
| Title: |
Nimodipine for primary degenerative, mixed and vascular dementia
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
The efficacy of nimodipine, a calcium channel blocker, has been tested in randomized controlled trials for the treatment of dementia, particularly Alzheimer's disease and multi-infarct dementia, the commonest forms of dementia in older people. The ratio...
|
| Date: |
Oct 2008
|
| Title: |
Haloperidol for agitation in dementia
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
Agitation is common in demented patients, and often takes the form of wandering, crying out, and aggression. It is presumed to reflect subjective distress and is associated both with risks to the patient and an increase in caregiver burden. In the prese...
|
| Date: |
Sep 2008
|
| Title: |
Alpha lipoic acid for dementia
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
Alpha lipoic acid (ALA) is one of a number of potent antioxidants for which a potential therapeutic role in dementia has been postulated. This suggestion arises from the possibility that oxidative and inflammatory processes contribute to the neurodegene...
|
| Date: |
Jul 2008
|
| Title: |
Melatonin for cognitive impairment
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
There are a number of studies that suggest a relationship between decline of melatonin function and the symptoms of dementia. Evidence from three randomized, placebo controlled trials, designed to evaluate melatonin for sleep disorders associated with d...
|
| Date: |
Jun 2008
|
| Title: |
Dementia and depression
|
| Publisher: |
Better Health Channel
|
| Description: |
Depression is very common among people with dementia. Carers should know the signs of depression can include poor sleep, poor appetite, lack of energy and feelings of guilt. Depression may also be a side-effect of medication.
|
| Date: |
May 2008
|
| Title: |
Aspirin for vascular dementia
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
Vascular dementia results from changes in the blood supply to the brain. This may occur from blockages in the arterial and/or capillary systems. Aspirin decreases TXA2 synthesis without significantly reducing prostacyclin synthesis thus causing reduced ...
|
| Date: |
May 2008
|
| Title: |
Cholinesterase inhibitors for dementia with Lewy bodies
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
The characteristic features of dementia with Lewy bodies are dementia, marked fluctuation of cognitive ability, early and persistent visual hallucinations and spontaneous motor features of Parkinsonism. Other symptoms are repeated falls, syncope, transi...
|
| Date: |
Apr 2008
|
| Title: |
Propentofylline for dementia
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
Propentofylline is a novel putatively neuroprotective agent that acts by inhibiting the uptake of adenosine and blocking the enzyme phosphodiesterase. Although a number of randomized controlled trials have been undertaken, data were available from only ...
|
| Date: |
Apr 2008
|
| Title: |
Piracetam for dementia or cognitive impairment
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
Piracetam was one of the first drugs used for dementia and comes from the class of drugs called nootropics, whose putative actions are still poorly defined. Most of the trials of piracetam were undertaken many years ago and did not use methods which wou...
|
| Date: |
Apr 2008
|
| Title: |
Hormone replacement therapy to maintain cognitive function in women with dementia
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
After the menopause, in women levels of estrogens decline. Estrogen replacement therapy (ERT) or replacement therapy with both estrogens and progestagens (hormone replacement therapy or HRT) might theoretically help to maintain cognitive function in pos...
|
| Date: |
Apr 2008
|
| Title: |
Ginkgo biloba for cognitive impairment and dementia
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
Ginkgo biloba appears to be safe in use with no excess adverse effects compared with placebo. Many of the early trials used unsatisfactory methods, were small, and publication bias cannot be excluded. Overall, evidence that Ginkgo has predictable and cl...
|
| Date: |
Mar 2008
|
| Title: |
Procaine treatments for cognition and dementia
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
Preparations which contain procaine as a component are widely promoted and used in several countries....
|
| Date: |
Jan 2008
|
| Title: |
Acetyl-l-carnitine for dementia
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
Acetyl-l-carnitine (ALC) is derived from carnitine and is described as having several properties which may be beneficial in dementia. Early studies suggested a beneficial effect of ALC on cognition and behaviour in aging subjects. However, later, larger...
|
| Date: |
Nov 2007
|
| Results 1 to 20 displayed. |
|
1
2
|
|
